Armetheon, Inc., is a privately held, San Francisco Bay area-based clinical stage biopharmaceutical company focused on the development of novel drug candidates for highly unmet needs in cardiovascular diseases. The company was founded by three experienced biotech entrepreneurs and pharmaceutical executives with years of drug R&D and company-building experience.
Armetheon Announces European Medicines Agency’s Support for 1000 Patient Single Phase 3 Study prior to MAA Filing for its Novel Oral Anticoagulant TecarfarinMENIO PARK, Calif., Feb. 14, 2017 /PRNewswire/ – Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular …Read More »
Armetheon announces issuance of a new U.S. patent for its Phase 2 clinical stage novel oral antiarrhythmic budiodaroneMENIO PARK, Calif., Feb. 13, 2017 – Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, …Read More »
Armetheon’s late-clinical stage oral anticoagulant candidate – Tecarfarin – addresses a major unmet need – a medication with potentially fewer adverse and fatal drug reactions and expected compatibility with treatment plans for patients with prosthetic heart valves.
Budiodarone is a clinical-stage oral drug candidate that is being investigated for its potential to suppress life-threatening ventricular arrhythmias and device firing in patients with implantable cardioverter defibrillators (ICDs). Budiodarone reduced AF burden in a dose-dependent fashion with up to 75% reduction in the highest dose group in a Phase 2 study with 72 patients with atrial fibrillation.
Educating the Community
As we advance the clinical stages of testing for tecarfarin and budiodarone, we are sharing our story with healthcare providers at appropriate peer-reviewed forums.
Learn More Today
As we complete the late clinical stage for Tecarfarin, we’d like to share our story with healthcare providers. Physicians and their patients could benefit from Armetheon’s novel drug development approach. Please contact us for more information.